Oligohydramnios: A Clinical Review

Written By Danial Mirza

Definition

Oligohydramnios is a clinical condition defined by a pathological reduction in the volume of amniotic fluid relative to the expected amount for a given gestational age (1). It is crucial for the junior clinician to understand that oligohydramnios is not a standalone disease but a critical clinical sign—a manifestation of an underlying disruption in the delicate homeostasis of amniotic fluid. This disruption may originate from fetal, placental, or maternal pathologies, and its identification is a pivotal marker for potential fetal compromise, associated with significantly increased perinatal morbidity and mortality (1, 4). At the most severe end of this spectrum lies anhydramnios, a condition defined by the complete or near-complete absence of measurable amniotic fluid, which carries a particularly grave prognosis, often stemming from lethal fetal anomalies or severe, early-onset placental failure (7).

The diagnosis is established non-invasively through transabdominal ultrasonography, using one of two principal quantitative methods (1):

  • Amniotic Fluid Index (AFI): A diagnosis is made with an AFI of ≤ 5 cm.

  • Single Deepest Vertical Pocket (SDP): A diagnosis is made with an SDP of < 2 cm.

High-Yield Point: A paradigm shift in clinical practice has led major bodies, including the American College of Obstetricians and Gynecologists (ACOG), to recommend using the Single Deepest Vertical Pocket (SDP) measurement as the preferred diagnostic method (6). Extensive evidence shows that the AFI method tends to over-diagnose oligohydramnios. This over-diagnosis can trigger a cascade of iatrogenic harm, including significantly higher rates of labour induction and subsequent emergency Caesarean sections for non-reassuring fetal status, without any corresponding improvement in perinatal outcomes (3). Adopting the SDP method is a key strategy to reduce unnecessary medical intervention and its associated maternal morbidity.

Epidemiology

Oligohydramnios is a relatively common finding in obstetric practice, complicating approximately 0.5% to 5.5% of all pregnancies (2). This significant variation in reported rates is largely attributable to differences in the populations studied (e.g., low-risk vs. high-risk cohorts) and, importantly, the diagnostic criteria employed (AFI vs. SDP) (17).

  • Influence of Gestational Age: The likelihood of developing oligohydramnios is not uniform across gestation. The incidence rises dramatically in pregnancies that extend beyond term, complicating as many as 12% of pregnancies continuing beyond 41 weeks (2). This is attributed to a combination of a natural physiological decline in amniotic fluid volume and placental senescence, where the aging placenta becomes less efficient, leading to a state of chronic, low-grade uteroplacental insufficiency (1). In contrast, oligohydramnios is an uncommon diagnosis in preterm gestations (<1%), but its presence, particularly when diagnosed before 24 weeks during the critical period of organogenesis, carries a much more guarded prognosis due to the high risk of lethal pulmonary hypoplasia (10, 13).

  • Malaysian and Regional Context: While large-scale epidemiological studies on the prevalence of oligohydramnios within Malaysia are scarce (27, 28), clinicians can infer risk by examining the prevalence of its underlying causes. The high prevalence of severe maternal anaemia in Southeast Asia (estimated at 50.17%) and documented maternal nutritional deficiencies in Malaysia are significant public health concerns (32, 33). These conditions are established risk factors for poor placental development and function. Therefore, a patient presenting with these comorbidities should have a heightened index of suspicion for uteroplacental insufficiency and its sequelae, including FGR and oligohydramnios. This approach encourages a proactive, risk-stratified model of antenatal care.

Etiology

A systematic approach is essential for diagnosis. While the list of causes is extensive, the two most frequently encountered etiologies in practice are preterm prelabour rupture of membranes (PPROM) and uteroplacental insufficiency (UPI) (18).

Fetal Causes

These relate to an intrinsic problem with the fetus, primarily its ability to produce or excrete urine.

  • Renal & Urinary Tract Anomalies: A direct failure of the "factory" (kidneys) or "plumbing" (urinary tract).

    • Bilateral Renal Agenesis (Potter's Syndrome): A lethal condition leading to anhydramnios and severe pulmonary hypoplasia (13).

    • Bilateral Multicystic Dysplastic Kidneys: Kidneys are replaced by non-functioning cysts (17).

    • Obstructive Uropathy: Blockage preventing urine excretion, such as posterior urethral valves (PUV) in male fetuses (17).

  • Fetal Growth Restriction (FGR): Often a parallel consequence of placental insufficiency, where the "brain-sparing" reflex reduces renal perfusion (2).

  • Post-term Pregnancy: Gestation >42 weeks, linked to placental aging (2).

  • Chromosomal Anomalies: Aneuploidies like Trisomy 13 and 18 are often associated with structural defects, including renal anomalies or severe FGR, which independently cause oligohydramnios (2).

  • Congenital Infections: Intrauterine infections like Cytomegalovirus (CMV) or Toxoplasmosis can cause direct fetal organ damage or placentitis, leading to UPI (8).

  • Fetal Demise: After fetal death, amniotic fluid production ceases and the fluid is gradually reabsorbed (2).

Placental Causes

These relate to a primary failure of the placenta to support the fetus.

  • Uteroplacental Insufficiency (UPI): A broad functional diagnosis representing inadequate placental perfusion. It is the final common pathway for many maternal conditions (1).

  • Placental Abruption: A chronic abruption can lead to ongoing placental damage and insufficiency (1).

  • Placental Thrombosis or Infarction: Occlusion of placental vessels reduces the functional capacity of the organ (8).

  • Twin-to-Twin Transfusion Syndrome (TTTS): In monochorionic twins, the hypovolemic "donor" twin has reduced renal perfusion, leading to severe oligohydramnios (the "stuck twin" phenomenon) (6).

Maternal Causes

These are systemic maternal conditions that secondarily affect placental function.

  • Hypertensive Disorders: Pre-eclampsia and chronic hypertension cause maternal vasculopathy, leading to poor perfusion of the placental bed (1).

  • Pre-existing Diabetes Mellitus: Particularly with end-organ vasculopathy, which is a strong risk factor for UPI (2).

  • Autoimmune Diseases: SLE and Antiphospholipid Syndrome (APS) can cause widespread inflammation and thrombosis, severely compromising placental blood flow (8).

  • Severe Maternal Dehydration: Can cause a transient reduction in uteroplacental perfusion (2).

Other Causes

  • Prelabour Rupture of Membranes (PROM/PPROM): A very common cause, resulting from a direct leak of fluid (2).

  • Iatrogenic (Drug-Induced):

    • NSAIDs (e.g., indomethacin): Inhibit prostaglandins, which are crucial for maintaining fetal renal blood flow, leading to oliguria (12).

    • ACE Inhibitors: Known teratogens that block fetal renal development and function, causing anuria (12).

  • Idiopathic: In many cases, especially at term, no cause is found. This may represent subclinical or early-stage placental insufficiency (1).

Pathophysiology

Amniotic fluid volume is a dynamic balance between production (inflow) and clearance (outflow), with a rapid exchange rate. Oligohydramnios occurs when this equilibrium shifts towards a net deficit.

  • Primary Inflow Sources:

    • Fetal Urination: This is the single most important source from the second trimester onwards. Fetal urine production increases from ~100 mL/day at 20 weeks to over 1 litre per day at term (1, 2). This directly explains why fetal renal function is paramount.

    • Fetal Lung Secretions: The fetal lungs actively secrete a substantial volume of fluid, contributing significantly to the AFV (2).

  • Primary Outflow Pathways:

    • Fetal Swallowing: This is the principal mechanism for fluid removal. The fetus swallows up to 1000 mL per day at term, which is absorbed and recirculated (1).

    • Intramembranous Absorption: This crucial but often overlooked pathway involves the direct transfer of water from the amniotic cavity into fetal blood vessels on the placental surface (20).

The three core pathophysiological mechanisms leading to oligohydramnios are:

  1. Reduced Fetal Urine Production: This is most often a consequence of uteroplacental insufficiency (UPI). Chronic fetal hypoxia triggers the vital "brain-sparing" reflex, where the fetus redistributes cardiac output to preserve the brain and heart. This comes at the expense of perfusion to the kidneys and lungs. The resulting decrease in renal blood flow leads directly to oliguria and, consequently, oligohydramnios (1, 17).

  2. Excessive Fluid Loss: This is most classically represented by rupture of the amniotic membranes (PPROM). A defect in the membranes allows for a direct "plumbing leak" of fluid from the uterus (2).

  3. Anatomic Defects: This involves a fundamental defect in the fetal urinary system. It can be a "factory" problem where urine is not produced (e.g., bilateral renal agenesis) or a "plumbing" problem where urine is produced but cannot be excreted (e.g., posterior urethral valves) (2, 10).

Clinical Presentation

The majority of women with oligohydramnios, particularly when it develops gradually, are entirely asymptomatic. The diagnosis is frequently an incidental finding on an ultrasound performed for other indications (7).

Diagnostic Clues

  • History:

    • Sensation of leaking fluid: This is the cardinal symptom of ruptured membranes. The clinician must ask specifically about a distinct "gush" of fluid, but also about more subtle presentations like persistent vaginal dampness or a watery discharge requiring sanitary pads (1).

    • Decreased fetal movement: A maternal perception of reduced fetal activity is a common, albeit non-specific, complaint. A persistent decrease is a red flag for potential fetal compromise and must always be investigated promptly (1).

    • Symptoms of underlying disease: The patient's complaint may be related to the underlying cause, such as headache in pre-eclampsia or abdominal pain in placental abruption.

  • Physical Examination:

    • Symphysis-fundal height (SFH) smaller than expected for gestational age: An SFH lagging by more than 3 cm is a standard indication for referral for an ultrasound assessment (1).

    • Abdominal Palpation: On palpation, the uterus may feel "compact" and unexpectedly "full of baby." The fetal parts may be much more easily palpated and outlined than would be expected, due to the diminished volume of cushioning amniotic fluid (2).

⚠️ Red Flag Signs & Symptoms

  • Sudden gush of fluid from the vagina: Highly suggestive of PPROM.

  • Persistent absence of fetal movements: A critical warning sign that may indicate chronic fetal hypoxia.

  • Signs of severe pre-eclampsia (severe headache, visual changes, epigastric pain): Indicates a severe underlying maternal disease causing UPI.

Complications

Severe and prolonged oligohydramnios, especially with early onset, leads to a recognizable pattern of fetal complications from uterine compression.

  • Pulmonary Hypoplasia: This is the most critical and life-limiting consequence. The lack of fluid for fetal "breathing" movements, particularly during the canalicular stage of lung development (16-26 weeks), prevents normal alveolar development and is often lethal postnatally (6).

  • Limb Deformities: The constant compression restricts movement, leading to joint contractures and abnormal positioning, such as talipes equinovarus (clubfoot) and other positional deformities (12).

  • Potter Sequence: This is the classic, tragic constellation of findings that results from severe, early-onset oligohydramnios or anhydramnios:

    • Potter Facies: A distinctive facial appearance with a flattened nose, recessed chin, low-set ears, and prominent epicanthic folds, all resulting from direct compression in utero (19).

    • Limb Deformities.

    • Pulmonary Hypoplasia.

  • Umbilical Cord Compression: The loss of the protective fluid buffer makes the umbilical cord highly vulnerable to compression between the fetus and the uterine wall, particularly during contractions. This can lead to intermittent obstruction of blood flow, which manifests as variable decelerations on the cardiotocograph (CTG) and can precipitate acute fetal distress (17).

  • Intrauterine Growth Restriction (IUGR): Oligohydramnios and IUGR are very frequently found together. They are not causally related but are rather two parallel consequences of a single underlying pathology: uteroplacental insufficiency (6).

Prognosis

The prognosis is highly dependent on the underlying cause, the gestational age at onset, and the severity of the fluid deficit.

  • Poor Prognosis: This is strongly associated with severe, early-onset oligohydramnios (diagnosed <24 weeks) or the presence of lethal fetal anomalies like bilateral renal agenesis. The primary cause of neonatal death in these cases is lethal pulmonary hypoplasia (10).

  • Favourable Prognosis: The outcome is generally better for isolated oligohydramnios diagnosed at or near term. In these cases, the fetus is mature and the primary risk is related to potential umbilical cord compression during labour, which can be mitigated with careful monitoring (16).

Differential Diagnosis

When a clinician encounters a uterus that is small for gestational age, the primary differentials to consider are:

  • [Oligohydramnios]: The primary diagnosis confirmed by ultrasound measurement of amniotic fluid.

  • [Intrauterine Growth Restriction (FGR)]: This is a key differential because a growth-restricted fetus leads to a smaller uterus. However, FGR and oligohydramnios are not mutually exclusive; they often coexist as parallel consequences of a single underlying cause: uteroplacental insufficiency. Finding one should always prompt a diligent search for the other.

  • [Wrong Dates]: An error in gestational age dating is a common and benign cause of a size-date discrepancy. This is distinguished by confirming the last menstrual period and, most reliably, by reviewing an early dating scan (first trimester), which is the most accurate method for establishing gestational age.

Investigations

A systematic investigation is required to confirm the diagnosis, identify the etiology, and assess fetal well-being.

Immediate & Bedside Tests

  • Sterile Speculum Examination: This is the priority if ruptured membranes are suspected.

    • Direct Visualization: Look for pooling of clear fluid in the posterior fornix or leakage from the cervical os (1).

    • Nitrazine Test: Amniotic fluid is alkaline (pH 7.1-7.3) and turns the yellow paper blue. Beware of false positives from blood, semen, or certain infections (1).

    • Ferning Test: A dried sample of amniotic fluid forms a characteristic arborizing, "fern-like" pattern under a microscope. This is highly specific (1).

Diagnostic Workup

  • Obstetric Ultrasound (Gold Standard): This is the definitive investigation.

    • AFV Quantification: Confirms the diagnosis using SDP (<2 cm) or AFI (≤5 cm) (1).

    • Fetal Biometry: Calculates an Estimated Fetal Weight (EFW) to diagnose or exclude FGR (9).

    • Detailed Anomaly Scan: A mandatory, comprehensive survey of fetal anatomy, paying special attention to the fetal urinary system (presence and appearance of both kidneys, bladder filling, ureters) to rule out structural causes (9).

  • Maternal Investigations: Guided by clinical suspicion. May include a full pre-eclampsia workup (FBC, Renal Profile, Liver Function Tests, Urine Protein) or TORCH serology for infection (8).

  • Invasive Fetal Testing (Amniocentesis): Offered if structural anomalies or severe, early-onset FGR are found, to test for chromosomal abnormalities (1).

Monitoring & Staging

  • Doppler Velocimetry: A critical tool to functionally assess the feto-placental unit.

    • Umbilical Artery (UA) Doppler: Assesses placental resistance. The development of Absent or Reversed End-Diastolic Flow (AREDV) is an ominous sign of severe UPI and a high risk of adverse perinatal outcome, including stillbirth (12).

    • Middle Cerebral Artery (MCA) Doppler: Assesses for the "brain-sparing" phenomenon. A low Pulsatility Index (PI) indicates vasodilation to maintain oxygen supply to the brain. The Cerebroplacental Ratio (CPR), which compares the MCA and UA Dopplers, is a more sensitive marker of fetal compromise (13).

  • Cardiotocography (CTG) / Non-Stress Test (NST): Provides a snapshot of fetal heart rate patterns. A "reactive" NST is generally reassuring of fetal well-being at that moment (11).

  • Biophysical Profile (BPP): A more comprehensive ultrasound-based assessment of fetal status, combining an NST with four other parameters: fetal breathing movements, gross body movements, fetal tone, and AFV. A score of 8/10 or 10/10 is normal; a score of ≤4/10 is abnormal and strongly associated with fetal compromise, usually prompting delivery (12).

Management

Management must be individualized based on three paramount factors: gestational age, underlying etiology, and the current state of fetal well-being. For most cases at term, the only definitive treatment is delivery.

Management Principles

  • The primary goal in preterm pregnancies is to prolong gestation safely to allow for fetal maturation, balancing this against the risks of ongoing intrauterine compromise.

  • The primary goal in term pregnancies is to proceed with delivery to avoid the risks of placental dysfunction or cord compression.

  • Shared decision-making with the patient and her family is a cornerstone of management.

Acute Stabilisation (for PPROM)

  • Admit to hospital for maternal and fetal monitoring.

  • Administer a course of antenatal corticosteroids to promote fetal lung maturity if preterm (<34-37 weeks).

  • Administer prophylactic antibiotics (e.g., a course of oral erythromycin) to prolong the latency period and reduce the risk of chorioamnionitis and neonatal infection (44).

Definitive Therapy (Timing of Delivery)

  • Isolated Oligohydramnios at Term:

    • Delivery is recommended. The ideal window is between 36 weeks 0 days and 37 weeks 6 days, or at the time of diagnosis if later (6, 47). This proactive approach is justified because even "isolated" oligohydramnios may be the first sign of placental dysfunction, and at term, the risks of expectant management may outweigh the minimal risks of delivering a mature infant.

  • Oligohydramnios with FGR:

    • With AREDV in Umbilical Artery: This is a sign of severe fetal compromise. Delivery is typically recommended between 30 and 34 weeks after a course of corticosteroids, often via elective Caesarean section (38).

    • With normal or mildly abnormal Dopplers: Delivery can often be deferred with intensive surveillance, but is typically recommended no later than 37 to 39 weeks (38).

  • Lethal Fetal Anomaly (e.g., Renal Agenesis):

    • The focus of care shifts entirely to perinatal palliative care. This involves a sensitive, multidisciplinary approach (obstetrician, neonatologist, palliative care specialist) to develop a birth plan that focuses on providing comfort, dignity, and compassionate care for the infant after birth, respecting the family's wishes (45).

Key Nursing & Monitoring Instructions

  • Continuous CTG monitoring during labour is mandatory due to the high risk of umbilical cord compression.

  • For PPROM, monitor closely for signs of chorioamnionitis (fever, maternal/fetal tachycardia, uterine tenderness, purulent vaginal discharge).

  • Be prepared for a significantly higher rate of emergency Caesarean section due to non-reassuring fetal status. In cases of severe preterm FGR with AREDV, an elective Caesarean section is often the most appropriate mode of delivery to avoid intrapartum hypoxia (38).

When to Escalate

Call Your Senior (MO/Specialist) if:

  • The CTG becomes non-reassuring (e.g., recurrent variable decelerations unresponsive to position change, late decelerations, or sustained bradycardia).

  • Doppler studies show acute deterioration, especially the development of AREDV or an abnormal ductus venosus waveform.

  • The Biophysical Profile score is equivocal (6/10), requiring discussion, or abnormal (≤4/10), requiring urgent action.

  • The mother develops signs of severe pre-eclampsia or chorioamnionitis.

Referral Criteria

  • Refer to a Fetal Medicine Specialist for all cases of severe oligohydramnios diagnosed before the third trimester, or whenever a major fetal structural anomaly is suspected or diagnosed.

References

  1. Oligohydramnios - StatPearls - NCBI Bookshelf. (n.d.). Retrieved July 15, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK562326/

  2. Oligohydramnios (Causes, Symptoms, and Treatment) - Patient.info. (n.d.). Retrieved July 15, 2025, from https://patient.info/doctor/oligohydramnios

  3. Amniotic Fluid: Physiology and Assessment | Article | GLOWM. (n.d.). Retrieved July 15, 2025, from https://www.glowm.com/article/heading/vol-4--fetal-development-and-maternal-adaptation--amniotic-fluid-physiology-and-assessment/id/410553

  4. Amnionic Fluid | Williams Obstetrics, 25e | AccessMedicine | McGraw Hill Medical. (n.d.). Retrieved July 15, 2025, from https://accessmedicine.mhmedical.com/content.aspx?aid=1160773371

  5. Embryology, Amniotic Fluid - StatPearls - NCBI Bookshelf. (n.d.). Retrieved July 15, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK541089/

  6. Sonography Evaluation of Amniotic Fluid - StatPearls - NCBI Bookshelf. (n.d.). Retrieved July 15, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK570623/

  7. Oligohydramnios | Concise Medical Knowledge - Lecturio. (n.d.). Retrieved July 15, 2025, from https://www.lecturio.com/concepts/oligohydramnios/

  8. Oligohydramnios - Wikipedia. (n.d.). Retrieved July 15, 2025, from https://en.wikipedia.org/wiki/Oligohydramnios

  9. Management of Oligohydramnios - WISDOM. (n.d.). Retrieved July 15, 2025, from https://wisdom.nhs.wales/health-board-guidelines/swansea-bay-maternity-file/management-of-oligohydramniossbuhb-maternity-guideline-2022pdf/

  10. Oligohydramnios - MD Searchlight. (n.d.). Retrieved July 15, 2025, from https://mdsearchlight.com/child-health/oligohydramnios/

  11. Oligohydramnios - Gynecology and Obstetrics - MSD Manual Professional Edition. (n.d.). Retrieved July 15, 2025, from https://www.msdmanuals.com/professional/gynecology-and-obstetrics/antenatal-complications/oligohydramnios

  12. Oligohydramnios - Gynecology and Obstetrics - Merck Manual Professional Edition. (n.d.). Retrieved July 15, 2025, from https://www.merckmanuals.com/professional/gynecology-and-obstetrics/antenatal-complications/oligohydramnios

  13. Oligohydramnios - Amniotic fluid - The Fetal Medicine Foundation. (n.d.). Retrieved July 15, 2025, from https://fetalmedicine.org/education/fetal-abnormalities/amniotic-fluid/oligohydramnios

  14. Amniotic fluid index | Radiology Reference Article | Radiopaedia.org. (n.d.). Retrieved July 15, 2025, from https://radiopaedia.org/articles/amniotic-fluid-index

  15. Clinico-epidemiologic profile and perinatal outcome of patients with oligohydramnios in third trimester in a tertiary care hospital | International Journal of Reproduction, Contraception, Obstetrics and Gynecology. (n.d.). Retrieved July 15, 2025, from https://www.ijrcog.org/index.php/ijrcog/article/view/12933

  16. Amniotic Fluid Disorders: From Prenatal Management to Neonatal Outcomes - PMC. (n.d.). Retrieved July 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC10047002/

  17. Amniotic Fluid: Physiology and Assessment | GLOWM. (n.d.). Retrieved July 15, 2025, from https://www.glowm.com/section-view/heading/Amniotic%20Fluid:%20Physiology%20and%20Assessment/item/208

  18. Oligohydramnios - Causes - Treatment - Prognosis - TeachMeObGyn. (n.d.). Retrieved July 15, 2025, from https://teachmeobgyn.com/pregnancy/fetal-abnormality/oligohydramnios/

  19. Oligohydramnios - Texas Children's Hospital. (n.d.). Retrieved July 15, 2025, from https://www.texaschildrens.org/content/conditions/oligohydramnios

  20. Regulation of amniotic fluid volume: insights derived from amniotic fluid volume function curves - PMC - PubMed Central. (n.d.). Retrieved July 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC6230884/

  21. Magnitude and associated factors of adverse perinatal ... - Frontiers. (n.d.). Retrieved July 15, 2025, from https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2022.958617/full

  22. (PDF) PREVALENCE OF PREGNANT WOMEN WITH OLIGOHYDRAMNIOS AND ITS EFFECT ON MATERNAL AND FETAL OUTCOME - ResearchGate. (n.d.). Retrieved July 15, 2025, from https://www.researchgate.net/publication/377198218_PREVALENCE_OF_PREGNANT_WOMEN_WITH_OLIGOHYDRAMNIOS_AND_ITS_EFFECT_ON_MATERNAL_AND_FETAL_OUTCOME

  23. Oligohydramnios: a prospective study of fetal, neonatal and maternal outcomes in low-middle income countries - PubMed Central. (n.d.). Retrieved July 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC6993413/

  24. Perinatal outcome in cases of severe oligohydramnios - IMSEAR. (n.d.). Retrieved July 15, 2025, from https://imsear.searo.who.int/items/f2d39fce-2019-4706-9dda-9a5fe7a6a782

  25. (PDF) Prevalence and associated factors of oligohydramnios in pregnancies beyond 36 weeks of gestation at a tertiary hospital in southwestern Uganda - ResearchGate. (n.d.). Retrieved July 15, 2025, from https://www.researchgate.net/publication/362428482_Prevalence_and_associated_factors_of_oligohydramnios_in_pregnancies_beyond_36_weeks_of_gestation_at_a_tertiary_hospital_in_southwestern_Uganda

  26. Oligohydramnios - March of Dimes. (n.d.). Retrieved July 15, 2025, from https://www.marchofdimes.org/find-support/topics/planning-baby/oligohydramnios

  27. Oligohydramnios : A risk of adverse perinatal outcomes - UNIMAS ... (n.d.). Retrieved July 15, 2025, from https://ir.unimas.my/id/eprint/42465/

  28. Clinical Guidelines - Malaysian Oncological Society. (n.d.). Retrieved July 15, 2025, from https://mymos.my/clinical-guidelines/

  29. Handbook of Obstetrics Guideline. Ministry of Health Malaysia MOH/P/PAK/534.24(GU)-e. (n.d.). Retrieved July 15, 2025, from https://www.researchgate.net/publication/383670610_Handbook_of_Obstetrics_Guideline_Ministry_of_Health_Malaysia_MOHPPAK53424GU-e

  30. Guidelines - Obstetrical & Gynaecological Society of Malaysia. (n.d.). Retrieved July 15, 2025, from https://www.ogsm.org.my/guidelines_gen.php

  31. Prevalence and associated factors of oligohydramnios in pregnancies beyond 36 weeks of gestation at a tertiary hospital in southwestern Uganda - PubMed. (n.d.). Retrieved July 15, 2025, from https://pubmed.ncbi.nlm.nih.gov/35918640/

  32. Nutrient intakes of pregnant and lactating women in Indonesia and Malaysia: Systematic review and meta-analysis - Frontiers. (n.d.). Retrieved July 15, 2025, from https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1030343/full

  33. Prevalence and Predictors of Anaemia Among Women of Reproductive Age in South and Southeast Asia - PMC. (n.d.). Retrieved July 15, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC10770578/

  34. Oligohydramnios (Low Amniotic Fluid) - Children's Hospital Colorado. (n.d.). Retrieved July 15, 2025, from https://www.childrenscolorado.org/conditions-and-advice/conditions-and-symptoms/conditions/oligohydramnios/

  35. Oligohydramnios: Causes, Symptoms, Diagnosis & Prevention - Cleveland Clinic. (n.d.). Retrieved July 15, 2025, from https://my.clevelandclinic.org/health/diseases/22179-oligohydramnios

  36. What are the key symptoms of oligohydramnios (low amniotic fluid) or polyhydramnios (excess amniotic fluid)? - Dr.Oracle AI. (n.d.). Retrieved July 15, 2025, from https://www.droracle.ai/articles/46512/oligohydramnios-or-polyhydramnios-key-symptoms-

  37. Oligohydramnios: Implications and Interventions. (n.d.). Retrieved July 15, 2025, from https://www.numberanalytics.com/blog/oligohydramnios-implications-interventions-pregnancy

  38. The investigation and management of the small-for ... - RCOG. (n.d.). Retrieved July 15, 2025, from https://www.rcog.org.uk/media/t3lmjhnl/gtg_31.pdf

  39. Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (interventional procedures overview) - NICE. (n.d.). Retrieved July 15, 2025, from https://www.nice.org.uk/guidance/ipg192/documents/therapeutic-amnioinfusion-for-oligohydramnios-during-pregnancy-excluding-labour-interventional-procedures-overview2

  40. ACOG Recommendations: When to Deliver Medically Complicated Pregnancies. (n.d.). Retrieved July 15, 2025, from https://www.obgproject.com/2023/01/17/acog-recommendations-when-to-deliver-medically-complicated-pregnancies/

  41. Foeto-maternal outcome in oligohydramnios - International Journal of Reproduction, Contraception, Obstetrics and Gynecology. (n.d.). Retrieved July 15, 2025, from https://www.ijrcog.org/index.php/ijrcog/article/download/11160/7129/40228

  42. Polyhydramnios - Diagnosis and treatment - Mayo Clinic. (n.d.). Retrieved July 15, 2025, from https://www.mayoclinic.org/diseases-conditions/polyhydramnios/diagnosis-treatment/drc-20368494

  43. Antenatal Fetal Surveillance - StatPearls - NCBI Bookshelf. (n.d.). Retrieved July 15, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK537123/

  44. Oligohydramnios - Low Amniotic Fluid | Children's Minnesota. (n.d.). Retrieved July 15, 2025, from https://www.childrensmn.org/services/care-specialties-departments/fetal-medicine/conditions-and-services/oligohydramnios/

  45. of fatal fetal anomalies and/or life-limiting conditions diagnosed during pregnancy perinatal palliative care - HSE. (n.d.). Retrieved July 15, 2025, from https://www.hse.ie/eng/about/who/acute-hospitals-division/woman-infants/bereavement-care/pathway-for-perinatal-palliative-care.pdf

  46. Version 2.0 Published December 2020 - Royal College of Physicians of Ireland. (n.d.). Retrieved July 15, 2025, from https://www.rcpi.ie/Portals/0/Document%20Repository/Institute%20of%20Obstetricians%20and%20Gynaecologists/National%20Clinical%20Guidelines/IOG_National%20Clinical%20Guidelines_Pathway%20for%20management%20of%20FFA%20andor%20life%20limiting%20conditions%20diagnosed%20during%20pregnancy_2020.pdf

  47. HANDBOOK OF OBSTETRICS GUIDELINE. (n.d.). Retrieved July 15, 2025, from https://www.moh.gov.my/moh/resources/Penerbitan/Perkhidmatan%20OnG%20&%20Ped/O%20&%20G/FINAL_DRAF_LAYOUT_Handbook_of_Obstetrics_Guideline_PDF.pdf

Danial Mirza
Previous

Induction of Labour: A Clinical Review
Next

A Clinical Review of Miscarriage